BAJAJ BROKING
Dr. Reddy’s acquired the Stugeron portfolio from Janssen Pharmaceutica NV for $50.5 million. The deal covers 18 APAC and EMEA markets, including India and Vietnam, giving it access to top-ranked Cinnarizine brands for the antivertigo segment.
Source: Dr. Reddy Press Release (NSE Exchange Fillings) | Published on Sept 11, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Dr. Reddy (NSE Exchange filings), the company, based in Hyderabad, has announced that it has entered a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to purchase the Stugeron portfolio for USD 50.5 million. The portfolio includes the well-known Stugeron, Stugeron Forte, and Stugeron Plus brands.
Also read: Adani Ports arm acquires Dependencia Logistics for ₹38 crore deal
Dr. Reddy’s acquires Stugeron portfolio for $50.5 million.
Deal spans 18 APAC and EMEA markets.
India and Vietnam identified as key regions.
Stugeron is a leading Cinnarizine-based brand.
Integration of operations to follow phased transition.
Also read: Biocon launches first US manufacturing site in New Jersey
The agreement encompasses 18 regions in the Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA) regions. Since the demand for antivertigo medicines is well established in India and Vietnam, they are the most important regions for the association. Dr. Reddy's will have responsibility for the Stugeron brand with its variants in geographies where we have a market for it.
Stugeron, which contains Cinnarizine as the active ingredient, is indicated for vestibular disturbances and vertigo. Its the number one agent in the Cinnarizine-represented pharmaceutical market (RPM) in India and number two in the overall anti-vertigo represented pharmaceutical market (eRPM). For you, since you're likely to track pharmaceutical news, this acquisition demonstrates how Dr. Reddy's is expanding their Central Nervous System (CNS) portfolio, along with an established product line.
Particulars | Details |
Acquirer | Dr. Reddy’s Laboratories Ltd. |
Seller | Janssen Pharmaceutica NV (J&J affiliate) |
Portfolio | Stugeron, Stugeron Forte, Stugeron Plus |
Value | $50.5 million |
Coverage | 18 markets (APAC and EMEA) |
Key Markets | India, Vietnam |
Therapeutic Segment | Anti-vertigo (Cinnarizine-based) |
On September 10, 2025 shares of Dr. Reddy's Laboratories ended 0.87% higher at ₹1,302.50 on the BSE at 15:30 PM IST; however, the stock has fallen by nearly 5% in 2025 so far. If you keep track of Dr. Reddy share price movements, then acquisition news can assist your perception of company movements and market trends.
This transaction is important to you because it helps affirm Dr. Reddy's presence in the antivertigo space while also expanding its CNS portfolio. It also gives you perspective for monitoring Dr. Reddy share price over the next few months as the company begins operations and integrates the portfolio across 18 markets. As an investor or industry observer, these developments will help you link products acquisition to higher themes of stock fluctuations and sector positioning.
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading